Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial

Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3 in the page footer.
    Difference
    0.1%
    Check dated 2026-03-11T14:22:29.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Updated the page to Revision 3.4.2. The government funding lapse notice and the prior Revision: v3.4.1 entry were removed.
    Difference
    0.4%
    Check dated 2026-02-11T09:48:20.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide notice about government funding lapse and NIH open status. Updated the site revision from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T10:22:27.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    UI and metadata changes include displaying the glossary option, adding 'No FEAR Act Data', and updating the Revision to v3.4.0, while removing the older items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and the older Revision v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T06:19:51.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Footer revision updated to v3.3.4 (replacing v3.3.3); no changes to study content or page functionality were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:18:38.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    Added a Locations section showing New York as a study site (Buffalo, NY). Removed the separate New York Locations reference and the HHS Vulnerability Disclosure entry, and updated the page revision to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T21:17:00.000Z thumbnail image

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.